DRMA Quote, Financials, Valuation and Earnings

MetaVia has a net margin of -- compared to Dermata Therapeutics's net margin of --. Dermata Therapeutics's return on equity of -- beat MetaVia's return on equity of --.

Dermata Therapeutics has a consensus price target of --, signalling upside risk potential of 331.66%. On the other hand MetaVia has an analysts' consensus of $16.00 which suggests that it could grow by 658.29%. Given that MetaVia has higher upside potential than Dermata Therapeutics, analysts believe MetaVia is more attractive than Dermata Therapeutics.

Dermata Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MetaVia has a beta of -0.223, suggesting its less volatile than the S&P 500 by 122.274%.

Dermata Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Dermata Therapeutics quarterly revenues are --, which are smaller than MetaVia quarterly revenues of --. Dermata Therapeutics's net income of -$3.2M is higher than MetaVia's net income of -$5.7M. Notably, Dermata Therapeutics's price-to-earnings ratio is -- while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics is -- versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Dermata Therapeutics's net margin of -49.65%. Dermata Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Dermata Therapeutics has a consensus price target of --, signalling upside risk potential of 331.66%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 496%. Given that NovaBay Pharmaceuticals has higher upside potential than Dermata Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Dermata Therapeutics.

Dermata Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Dermata Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Dermata Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Dermata Therapeutics's net income of -$3.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Dermata Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Dermata Therapeutics's net margin of -2357.27%. Dermata Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Dermata Therapeutics has a consensus price target of --, signalling upside risk potential of 331.66%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1207.69%. Given that Palatin Technologies has higher upside potential than Dermata Therapeutics, analysts believe Palatin Technologies is more attractive than Dermata Therapeutics.

Dermata Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Dermata Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Dermata Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Dermata Therapeutics's net income of -$3.2M is higher than Palatin Technologies's net income of -$7.8M. Notably, Dermata Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

ZyVersa Therapeutics has a net margin of -- compared to Dermata Therapeutics's net margin of --. Dermata Therapeutics's return on equity of -- beat ZyVersa Therapeutics's return on equity of --.

Dermata Therapeutics has a consensus price target of --, signalling upside risk potential of 331.66%. On the other hand ZyVersa Therapeutics has an analysts' consensus of $70.00 which suggests that it could grow by 1734.86%. Given that ZyVersa Therapeutics has higher upside potential than Dermata Therapeutics, analysts believe ZyVersa Therapeutics is more attractive than Dermata Therapeutics.

Dermata Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ZyVersa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dermata Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZyVersa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics pays -- of its earnings as a dividend. ZyVersa Therapeutics pays out -- of its earnings as a dividend.

Dermata Therapeutics quarterly revenues are --, which are smaller than ZyVersa Therapeutics quarterly revenues of --. Dermata Therapeutics's net income of -$3.2M is lower than ZyVersa Therapeutics's net income of -$2.4M. Notably, Dermata Therapeutics's price-to-earnings ratio is -- while ZyVersa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics is -- versus -- for ZyVersa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.